AMGN News and Press, Amgen Inc. From 05/29/24

2024-05-29 11:50:26 ET More on AstraZeneca AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca, Daiichi Sankyo ADC misses ke...

2024-05-29 08:15:00 ET If you're looking for an investment in the pharmaceutical sector and you don't already own shares of Amgen (NASDAQ: AMGN) , it might be worth considering a purchase. The company's development of highly technological cancer therapies is almost certain to expand...

2024-05-28 09:21:20 ET More on CytomX CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town CytomX slides after early data for Amgen-partnered cancer drug CytomX...

AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024 PR Newswire Data From Newly FDA-Approved IMDELLTRA™ (tarlatamab-dlle) Further Reinforce Leadership in Bispecific T-Cell Engagers Overall Survival Data from Phase 3 LUMAKRAS &#...

2024-05-28 08:30:00 ET Summary Novo Nordisk stock has easily outperformed the market over the past year. Novo Nordisk's growth potential through its weight loss drugs is expanding. Competition from rivals like Eli Lilly and Amgen could impact demand and pricing dynamics in the...

2024-05-27 10:05:29 ET Summary Arrowhead Pharmaceuticals' stock has dropped more than 70% from its June 2021 high, causing concerns about its near-term outlook. The company's lead therapy, plozasiran, is currently behind Ionis Pharmaceuticals' olezarsen for two hypertriglyceridemi...

2024-05-27 01:45:30 ET Summary Gilead is sitting at one of the lowest valuations in the Big Pharma sector, with a high and sustainable 4.6% dividend yield available for new buyers. The stock has an enviable track record of rising strongly in price when turmoil hits Wall Street and...

2024-05-26 15:19:39 ET Summary Eli Lilly's shares reached new all-time highs after the company increased full-year revenue and EPS guidance. The company's growth is currently supply-constrained and the growth of tirzepatide in the near- and possibly medium-term should only be limi...

2024-05-26 13:36:00 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety The FTC Cracks Down On Novo Nordisk's Ozempic SA Asks: Is Eli Lilly or Novo ...

2024-05-26 06:53:00 ET With some promising clinical trial results in hand and more that could be on the way relatively soon, Amgen 's (NASDAQ: AMGN) latest attempt to develop a therapy for obesity is looking like it could be a contender for the crown that's currently jointly held by...